Liposome combined medicine and method for preparing the same

A liposome and drug technology, applied in liposome delivery, pharmaceutical formulations, antibacterial drugs, etc., can solve the problems of blood white blood cell and thrombocytopenia, abnormal liver and kidney function, easy to cause phlebitis, etc., and achieve the goal of drug The effect of reducing the amount of distribution, reducing the number of medications, and enhancing the curative effect

Inactive Publication Date: 2008-01-02
HUNAN KANGDU PHARMA
View PDF0 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The severe toxic and side effects exposed clinically by the existing clindamycin, fleroxacin, ciprofloxacin, and levofloxacin drugs include: nausea, vomiting, abdominal pain, diarrhea, and enteritis in the gastrointestinal tract; toxicity to the liver and kidneys causes abnormal liver and kidney functi

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Liposome combined medicine and method for preparing the same
  • Liposome combined medicine and method for preparing the same
  • Liposome combined medicine and method for preparing the same

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0044] Example 1:

[0045] The formula used in this embodiment is as follows:

[0046] Soy lecithin and dipalmitoylcholine mixture (3∶1) 0.05mol

[0047] Cholesterol and β-sitosterol mixture (1∶1) 0.05mol

[0048] Any ratio mixture of clindamycin hydrochloride and levofloxacin lactate 200mg

[0049] Reduced glutathione and tiopronin mixture (molar ratio 1:3) 20g

[0050]Polyethylene glycol 6000 0.005mol

[0051] Sodium glutamate 30g

[0052] The mixture of Pluronic F68 and hydroxypropyl methylcellulose in any ratio contains 0.2%-0.7% g / ml in 100ml liquid

[0053] Add phosphate buffer 0.015M pH3.0-5.5 to 1000ml

[0054] The 200 mg mixture of clindamycin hydrochloride and levofloxacin lactate in any ratio is calculated based on the amount of clindamycin and levofloxacin.

[0055] Preparation steps:

[0056] (1) The mixture of soybean lecithin and dipalmitoylcholine and the mixture of cholesterol and β-sitosterol are dissolved in an appropriate amount of chloroform to prepare a solut...

Example Embodiment

[0066] Example 2:

[0067] The formula used in this embodiment is as follows:

[0068] Soy lecithin and dipalmitoylcholine mixture (5:1) 0.1mol

[0069] Cholesterol and β-sitosterol mixture (2∶1) 0.1mol

[0070] Any ratio mixture of clindamycin hydrochloride and levofloxacin hydrochloride 400mg

[0071] Reduced glutathione and tiopronin mixture (molar ratio 1:5) 30g

[0072] Polyethylene glycol 6000 0.001mol

[0073] Sodium glutamate 40g

[0074] The mixture of Pluronic F68 and hydroxypropyl methylcellulose in any ratio contains 0.2%-0.7% g / ml in 100ml liquid

[0075] Add phosphate buffer 0.015M pH3.0-5.5 to 1000ml

[0076] The 200 mg mixture of clindamycin hydrochloride and levofloxacin hydrochloride in any ratio is calculated based on the amount of clindamycin and levofloxacin hydrochloride.

[0077] Preparation steps: refer to Example 1.

[0078] Pharmacodynamic verification test:

[0079] The mouse model was infected with pneumococcus, 6 hours after infection, intravenous inje...

Example Embodiment

[0081] Example 3:

[0082] The formula used in this embodiment is as follows:

[0083] Soy lecithin and dipalmitoylcholine mixture 4:1) 0.2mol

[0084] Cholesterol and β-sitosterol mixture (2:1) 0.2mol

[0085] Any ratio mixture of clindamycin phosphate and levofloxacin lactate 600mg

[0086] Reduced glutathione and tiopronin mixture (molar ratio 1:4) 30g

[0087] Polyethylene glycol 6000 0.02mol

[0088] Sodium glutamate 50g

[0089] The mixture of Pluronic F68 and hydroxypropyl methylcellulose in any ratio contains 0.2%-0.7% g / ml in 100ml liquid

[0090] Add phosphate buffer 0.015M pH3.0-5.5 to 1000ml

[0091] The 200 mg mixture of clindamycin phosphate and levofloxacin lactate in any ratio is calculated based on the amount of clindamycin and levofloxacin.

[0092] Preparation steps: see Example 1.

[0093] Pharmacodynamic verification test:

[0094] The mouse model was infected with pneumococcus, 6 hours after infection, intravenous injection was administered once a day. The co...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a liposome compound and the preparing method, which is characterized in that said liposome compound comprises one or several compounds of clindamycinum, fleraxacin, levofloxacin hydrochloride and ciprofloxacin. The toxicity of product is low, medical effect is high and effective prevention of drug resistance generation by pathogenic microorganism.

Description

technical field [0001] The invention relates to a liposome combination medicine and a preparation method thereof. Background technique [0002] The existing antimicrobial drugs clindamycin, fleroxacin, ciprofloxacin, and levofloxacin are all broad-spectrum and highly effective antibacterial drugs. However, their clinical use faces two major crises: one is that the dosage is increasing, and the other is that the toxicity and side effects are obvious. The severe toxic and side effects exposed clinically by the existing clindamycin, fleroxacin, ciprofloxacin, and levofloxacin drugs include: nausea, vomiting, abdominal pain, diarrhea, and enteritis in the gastrointestinal tract; toxicity to the liver and kidneys causes abnormal liver and kidney function, or even damage; blood leukocytes and thrombocytopenia caused by toxicity to the blood system; allergic reactions cause rash, itchy skin, hives, dyspnea, and even anaphylactic shock; pain during injection Strong and prone to ph...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/127A61K31/496A61K31/7056A61K47/34A61P31/04A61K47/10
Inventor 蔡海德
Owner HUNAN KANGDU PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap